Pancreatic Cancer Gene-Edited Cell Lines for Drug Discovery

Pancreatic cancer is the seventh leading cause of cancer death globally, with an estimated 495,000 new cases and 466,000 deaths in 2020 (WHO GLOBOCAN). In the United States, the 5-year relative survival rate is 12% for all stages combined, dropping to 3% for distant-stage disease (NCI SEER). Key risk factors include smoking, chronic pancreatitis, obesity, diabetes, and family history. The late diagnosis and aggressive biology underscore the urgent need for better preclinical models.

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense desmoplastic stroma, high mutational heterogeneity, and early metastasis. Public datasets from TCGA (PanCancer Atlas), COSMIC, and DepMap provide extensive genomic and dependency profiles. Open questions include mechanisms of therapy resistance, tumor-stroma crosstalk, and synthetic lethal vulnerabilities. Gene-edited cell models enable precise dissection of these questions.

Pancreatic cancer arises through stepwise accumulation of mutations in precursor lesions (PanIN). Key pathways include:

• • KRAS signaling: Activating mutations (primarily G12D, G12V) drive MAPK and PI3K/AKT pathways.
• • TP53 inactivation: Loss of p53 function impairs apoptosis and cell cycle arrest.
• • CDKN2A loss: p16 inactivation disrupts RB-mediated cell cycle control.
• • SMAD4 loss: Disruption of TGF-beta signaling promotes invasion and metastasis.

Data from TCGA (PanCancer Atlas) and COSMIC (v99):

Key signaling networks in PDAC:

• • MAPK/ERK pathway: KRAS -> RAF -> MEK -> ERK. Hyperactivation drives proliferation.
• • PI3K/AKT/mTOR pathway: KRAS -> PI3K -> AKT -> mTOR. Promotes survival and metabolism.
• • TGF-beta pathway: SMAD4 loss leads to loss of growth inhibition and enhanced EMT.
• • Wnt/beta-catenin pathway: Upregulated in a subset of tumors, promoting stemness.
• • DNA damage repair: BRCA1/2, ATM, PALB2 mutations impair homologous recombination.

Common pancreatic cancer cell lines and their key mutations:

Organoid models recapitulate patient-specific heterogeneity and stroma interactions, offering advantages for drug testing and personalized medicine.

Common in vivo models:

• • Patient-derived xenografts (PDX): Maintain tumor heterogeneity, used for drug efficacy studies.
• • Genetically engineered mouse models (GEMM): e.g., KPC (LSL-KRAS G12D; LSL-TP53 R172H; Pdx1-Cre) recapitulates human PDAC progression.
• • Orthotopic and subcutaneous xenografts: Used for metastasis and drug testing.
• • Chemically induced models: e.g., DMBA-induced pancreatic cancer in rats.

CRISPR/Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications. Examples include:

• • TP53 knockout in PANC-1 or MIA PaCa-2: Models loss of p53 function.
• • KRAS G12D knock-in in BxPC-3 (KRAS wild-type): Converts wild-type to mutant.
• • CDKN2A knockout: Mimics p16 loss.
• • SMAD4 knockout: Models TGF-beta pathway disruption.

Commercially available, sequence-verified gene-edited cell lines accelerate research by providing reproducible, isogenic controls. These models are validated by Sanger sequencing, qPCR, and Western blot, and are free from off-target effects. They are used for drug screening, target validation, and mechanistic studies.

Knockout and knock-in lines are used to validate the role of specific genes in PDAC. For example:

• • TP53 knockout in MIA PaCa-2 confirms loss of apoptosis and cell cycle arrest.
• • KRAS G12D knock-in in BxPC-3 demonstrates MAPK pathway activation and increased proliferation.
• • SMAD4 knockout in PANC-1 enhances migration and invasion, confirming its role in metastasis suppression.

Isogenic pairs (e.g., wild-type vs. KRAS G12D knock-in) are used for drug screening to identify compounds that selectively target mutant cells. Resistance modeling: exposing isogenic lines to increasing drug concentrations reveals resistance mechanisms. For example, MEK inhibitor resistance in KRAS-mutant cells can be studied using isogenic lines.

CRISPR synthetic lethality screens identify genes that are essential only in the context of a specific mutation. For example, screens in KRAS-mutant cells have identified targets like TBK1, GATA2, and PLK1. These screens rely on isogenic pairs to control for genetic background.